Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis

Patients with psoriatic arthritis (PsA) experience impaired health-related quality of life (HRQoL). Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA, which has been associated with improvements in dermatologic endpoints in patients with PsA. To assess the extent to which tofaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Peter C., Bushmakin, Andrew G., Cappelleri, Joseph C., Young, Pamela, Germino, Rebecca, Merola, Joseph F., Yosipovitch, Gil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472763/
https://www.ncbi.nlm.nih.gov/pubmed/34575192
http://dx.doi.org/10.3390/jcm10184081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472763/
https://www.ncbi.nlm.nih.gov/pubmed/34575192
http://dx.doi.org/10.3390/jcm10184081

Ejemplares similares